Pulmonary hypertension: recognition, classification and specialist referral

Clinical scope and immediate priorities

Pulmonary hypertension is an elevated pulmonary vascular pressure state with multiple causes and very different treatments. The central clinical error is to treat an echocardiographic pressure estimate as a complete diagnosis. Classification by underlying mechanism is essential before disease-specific therapy is considered. Respiratory presentations often share symptoms while differing greatly in urgency. Oxygenation, work of breathing, gas exchange, infection risk, smoking or occupational exposure, and pre-existing lung disease should be integrated rather than interpreted as isolated findings. Objective testing should be matched to the clinical question and repeated when physiology is changing.

Recognition and differential diagnosis

Progressive exertional dyspnoea, fatigue, chest discomfort, presyncope, syncope and oedema are common. Examination may show a loud pulmonary component of S2, right ventricular heave, elevated jugular venous pressure or peripheral oedema. Symptoms are nonspecific and often attributed to lung disease, obesity or deconditioning until disease is advanced. The practical aim is to identify features that change urgency, distinguish common mimics and avoid anchoring on a single test result. Where the presentation is atypical, reassess the working diagnosis rather than forcing the findings to fit it.

Assessment and investigations

Echocardiography estimates probability and evaluates right ventricular structure and alternative left-heart causes. ECG, chest imaging, pulmonary function, oxygenation, V/Q scanning for chronic thromboembolic disease and targeted autoimmune or liver testing are selected according to phenotype. Right-heart catheterisation is required to confirm haemodynamics before pulmonary arterial hypertension therapy. Investigations should be sequenced so that urgent bedside information is obtained first, followed by tests that refine cause, severity or treatment choice. Trends, prior results and treatment effects often matter more than whether one value sits just inside or outside a reference range.

Initial and definitive management

Treat hypoxaemia and the underlying heart, lung or thromboembolic disease. Pulmonary arterial hypertension requires specialist-directed vasodilator therapy chosen according to haemodynamic and clinical risk. Chronic thromboembolic pulmonary hypertension may be surgically or interventionally treatable and should be actively identified rather than assumed to be irreversible. Treatment should address reversible causes and immediate physiological risk while preserving options for definitive care. Medication selection requires attention to allergies, interactions, renal or hepatic function, pregnancy where relevant, and the possibility that a medicine suitable in one health system may not be first-line in another.

Escalation, complications and special situations

Syncope, right-heart failure, rapidly worsening functional class or pregnancy in established PAH requires specialist management. General vasodilators or PAH-specific agents can worsen some non-PAH conditions and should not be initiated empirically outside an appropriate pathway. Escalate early when instability, organ dysfunction, rapidly progressive symptoms or a high-risk comorbidity is present. Frailty, pregnancy, immunosuppression, extremes of age and major renal or hepatic impairment can alter both presentation and treatment tolerance, so protocol-based care still requires individualisation.

International practice across English-speaking health systems

Across the United Kingdom, United States, Canada, Australia, New Zealand and Ireland, the core clinical principles are broadly similar, but drug licensing, formularies, emergency pathways, screening thresholds, referral criteria and professional scope can differ. Use the most recent national or regional guidance, local antimicrobial or medicines policy, and the relevant product information when an operational detail could change treatment. MDPDA therefore presents a common evidence-based framework and highlights areas that should be adapted locally rather than implying that one country’s pathway is universal.

Monitoring, follow-up and prevention

Follow-up should be purposeful rather than routine. Define what is being monitored, when it should be reassessed and what finding would change management. Review adherence and adverse effects, repeat objective measurements when they inform risk, and reconsider the diagnosis if the clinical course is inconsistent with expectations. Safety-netting should state which symptoms require urgent reassessment and which service should be contacted. For chronic disease, prevention, vaccination where relevant, smoking cessation, nutrition, physical activity and management of related cardiovascular or metabolic risk can be as important as disease-specific treatment. Specialist follow-up integrates functional class, exercise capacity, natriuretic peptides, imaging and haemodynamics where needed. Vaccination, contraception/pregnancy counselling and management of iron deficiency may be relevant.

Common pitfalls and safety checks

Do not diagnose pulmonary arterial hypertension from an echo-estimated pulmonary pressure alone. Consider chronic thromboembolic pulmonary hypertension because it can be specifically treated. PAH drugs are not interchangeable with therapy for left-heart or hypoxic pulmonary hypertension. Pregnancy carries major risk in advanced pulmonary vascular disease. A useful final check is to ask what dangerous alternative diagnosis could still explain the presentation, whether the patient has demonstrated an appropriate response to treatment, and whether the discharge or transfer plan is safe if symptoms recur.

Documentation, communication and shared decisions

Documentation should make the clinical reasoning visible. Record the key positive and negative findings, relevant risk stratification, important investigations, treatment rationale, discussions with the patient or family where appropriate, and the trigger for escalation or review. When care crosses settings, handover should identify unresolved diagnostic questions, medicines started or withheld, pending results and who is responsible for follow-up. Shared decisions are particularly important when more than one reasonable strategy exists or when treatment benefit must be balanced against bleeding, frailty, treatment burden or quality of life.

Implementation across care settings

Implementation across care settings should include a clear baseline of oxygenation, inhaled or respiratory medicines, smoking status, vaccination and previous exacerbation history. Confirm inhaler technique when inhaled therapy is relevant and distinguish treatment failure from poor delivery. Community and hospital teams should share microbiology, imaging and oxygen information so repeated episodes are interpreted in context. Where specialist respiratory testing is not immediately available, document the provisional diagnosis and arrange a defined reassessment rather than allowing temporary empiric treatment to become an unexamined long-term plan.

Quality and patient-safety review

Before closing the episode of care, confirm that the working diagnosis remains consistent with the observed course, that high-risk alternatives have been considered, and that treatment has not introduced a new avoidable hazard. Review allergies, interactions, renal or hepatic constraints, pregnancy considerations where relevant, and the patient’s ability to follow the plan. The safest pathway is one in which the next clinician can understand what has been decided, what remains uncertain and which finding should trigger escalation.

Applying evidence to the individual patient

Guidelines provide a framework, but safe implementation depends on the patient’s baseline function, comorbidities, concurrent medicines, treatment goals and access to follow-up. Recommendations should be interpreted in light of absolute rather than relative benefit where possible, and clinicians should identify when the evidence base under-represents older people, pregnancy, severe kidney or liver impairment, multimorbidity or other groups. When two reasonable options exist, explain the trade-offs and document the reason for the selected approach. If local policy differs from an international recommendation, determine whether this reflects formulary, service configuration, licensing or genuinely different evidence. Reassessment is part of evidence-based care: a working diagnosis or treatment plan that no longer fits the clinical course should be revised rather than defended simply because it matched the initial pathway.

Practical review checklist

Before finalising management, confirm that the severity has been classified correctly, essential investigations have been acted on, and any test still pending has a named clinician or service responsible for review. Reconcile regular medicines and temporary changes, check whether monitoring is required after initiation or dose adjustment, and make the follow-up interval proportionate to risk. Explain the plan in language the patient can use, including what improvement is expected, which adverse effects matter and which symptoms require urgent help. Where care is shared between primary, secondary, dental, pharmacy or community services, avoid ambiguous instructions such as ‘follow up as needed’; specify who should do what and when. This final systems check often prevents harm that is not caused by the clinical decision itself but by gaps in implementation.